购物车
- 全部删除
- 您的购物车当前为空
LH2-051是一种通过DAT-CDK9-TFEB通路激活溶酶体生物合成和清除Aβ聚集体的溶酶体增强先导化合物。在小鼠模型中,LH2-051显示出优良的药代动力学性质,具备改善阿兹海默症症状的潜力。
LH2-051是一种通过DAT-CDK9-TFEB通路激活溶酶体生物合成和清除Aβ聚集体的溶酶体增强先导化合物。在小鼠模型中,LH2-051显示出优良的药代动力学性质,具备改善阿兹海默症症状的潜力。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 询价 | 10-14周 | |
50 mg | 询价 | 10-14周 |
产品描述 | LH2-051 is a lysosomal-enhancing lead compound that stimulates lysosomal biosynthesis and the clearance of Aβ aggregates through the dopamine transporter-cell cycle protein dependent kinase 9-transcription factor EB (DAT-CDK9-TFEB) pathway. Demonstrating favorable pharmacokinetic properties in mouse models, LH2-051 has the potential to improve Alzheimer's disease outcomes. |
分子量 | 434.57 |
分子式 | C27H34N2O3 |
CAS No. | 2358754-22-8 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容